Biologists, physicists and computer scientists have joined a platform called RentAHuman.ai to advertise their skills.

Applied Digital's strong revenue pipeline and the new data center campus could help it exceed Wall Street's growth expectations. The stock is expensive right now, but it can justify its valuation ...

Medical device company Applied Medical has been awarded $381,705,005 in damages after a federal jury in California found Medtronic liable for violations of federal and state antitrust laws. In ...

Applied Digital (APLD) is restructuring by spinning out its cloud segment, ChronoScale, retaining 97% ownership, and targeting AI-optimized GPU cloud infrastructure. ChronoScale addresses persistent ...

Applied Digital (APLD 5.22%) has been one of the best stocks to own in 2025, rising around 260% so far this year although it has been incredibly volatile, rocketing up and down since October. Applied ...

Applied Digital Corp (NASDAQ: APLD) shares are trending on Monday. Here’s a look at what you need to know. What To Know: Applied Digital has shifted its primary focus from hosting Bitcoin mining ...

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting ...

Applied Digital (APLD) posted $64.2M in Q1 revenue with 84% growth while CoreWeave (CRWV) reported $1.36B in Q3 revenue with 134% growth. CoreWeave generated $51.9M in operating income and doubled its ...

Pope Leo XIV urged Lebanon’s leaders to embrace tenacity, dialogue and a renewed commitment to the common good during an address at the Presidential Palace in Baabda on Sunday, continuing his weeklong ...

Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics is laying off almost half of the biotech's workforce to conserve its ...

Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question whether the biotech will ever be able to get the drug to market. The New ...